Research report · October 30, 2026
FLRY3
Fleury S.A.
Reference price
R$ 20.47
Consensus across all agents
Research synthesis
Business quality is high — durable operations, strong finances, and a long record of profitability support resilience.
Margin of safety is weak — buyers today may be paying too much for a quality business already fully valued.
A more attractive entry price or clearer evidence of steadier earnings growth would strengthen the investment case.
Agent conviction.
Value & Moat agent
Warren Buffett
Scoring radar
Financial metrics.
Revenue vs net income
BRL thousands · 2014–2025
Balance sheet components
BRL thousands · 2014–2025
Leverage & efficiency
Moderate leverage - acceptable for healthcare.
Consistently positive operating margin with low variability.
Return on equity has consistently exceeded the cost of capital, indicating value creation.
Return on invested capital has consistently exceeded the cost of capital, indicating value creation.
Operating margin
% · 2014–2025
Ownership & distributions.
Voting ownership
| Shareholder | Voting % |
|---|---|
| Bradesco Group | 24.8% |
| Family Pardini | 19.7% |
| Free float | 55.5% |
Payout history
Dividend per share
R$ 0.863
Dec 2025
Dividend per share
R$ 0.931
Dec 2024
Dividend per share
R$ 0.494
Dec 2023
Dividend per share
R$ 0.238
Dec 2022